Cytel Inc., a global provider of innovative analytical software and services to the biopharmaceutical industry, today announces the release of version 2.0 of its EnForeSys software. The upgraded version unveils expanded functionality that allows users improved interactivity and the ability to generate even more granular forecasts for resolving their feasibility challenges.For more information about the capabilities of our 2.0 EnforeSys software, please listen to our podcast: What's New In EnForeSys 2.0 Trial Enrollment Predictive Software.
